{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:08:02Z","timestamp":1776776882475,"version":"3.51.2"},"reference-count":30,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"unspecified","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,3,14]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The effect of early antiplatelet therapy on 30-day mortality after coronary artery bypass grafting (CABG) remains uncertain. This study aimed to evaluate the association between early antiplatelet therapy initiation and clinical outcomes in post-CABG patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A retrospective target trial emulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Single academic medical centre in Boston, Massachusetts, USA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>We included adult patients who underwent CABG and were admitted to the intensive care unit at Beth Israel Deaconess Medical Center between 2008 and 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were classified into the treatment group if they initiated antiplatelet therapy within 24 hours postoperatively; otherwise, they were assigned to the control group. To address immortal-time bias for the primary outcome of 30-day mortality, we used clone-censor-weighting. For the exploratory outcome of 30-day acute kidney injury (AKI) incidence, we employed inverse probability of treatment weighting to balance baseline covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis for 30-day mortality included 6887 patients. The mortality was 2.35% in the control group versus 1.44% in the treatment group, yielding an absolute risk difference of 0.90% (control group minus treatment group, 95% CI 0.09% to 1.72%). The difference in restricted mean time lost was 0.19 days (control group minus treatment group, 95% CI 0.03 to 0.36). For AKI incidence, 5543 patients were analysed. The incidence was 78.61% in the control group and 69.13% in the treatment group, with an absolute difference of 9.48% (control group minus treatment group, 95% CI 6.40% to 12.50%; p&lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this target trial emulation, early antiplatelet therapy initiated within 24 hours after CABG was associated with lower 30-day mortality and a reduced incidence of postoperative AKI. These findings warrant confirmation in prospective randomised controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-113901","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:20:36Z","timestamp":1776774036000},"page":"e113901","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of early antiplatelet therapy on 30-day mortality after coronary artery bypass grafting: a retrospective target trial emulation using the MIMIC-IV database"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2191-4465","authenticated-orcid":false,"given":"Ying","family":"Jiang","sequence":"first","affiliation":[{"name":"Xuzhou Hospital of Traditional Chinese Medicine, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huafeng","family":"Ding","sequence":"additional","affiliation":[{"name":"Xuzhou Central Hospital, Xuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Su","sequence":"additional","affiliation":[{"name":"Xuzhou Central Hospital, Xuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4573-7949","authenticated-orcid":false,"given":"Xiangquan","family":"Li","sequence":"additional","affiliation":[{"name":"Xuzhou Central Hospital, Xuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"2026042105201717000_16.4.e113901.1","first-page":"1811","article-title":"Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","year":"2023","journal-title":"Lancet"},{"key":"2026042105201717000_16.4.e113901.2","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030165","article-title":"Burden of Ischemic Heart Disease and Its Attributable Risk Factors in North Africa and the Middle East, 1990 to 2019: Results From the GBD Study 2019","volume":"13","author":"Aminorroaya","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026042105201717000_16.4.e113901.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020798"},{"key":"2026042105201717000_16.4.e113901.4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/eurheartj\/ehae672","article-title":"Coronary artery bypass grafting vs. percutaneous coronary intervention in severe ischaemic cardiomyopathy: long-term survival","volume":"46","author":"Bloom","year":"2025","journal-title":"Eur Heart J"},{"key":"2026042105201717000_16.4.e113901.5","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/jocs.15283","article-title":"Anticoagulation and antiplatelet therapy post coronary artery bypass surgery","volume":"36","author":"Sembi","year":"2021","journal-title":"J Card Surg"},{"key":"2026042105201717000_16.4.e113901.6","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001039"},{"key":"2026042105201717000_16.4.e113901.7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.athoracsur.2024.12.026","article-title":"Long-Term Survival After Coronary Artery Bypass Graft Surgery","volume":"120","author":"Vyas","year":"2025","journal-title":"Ann Thorac Surg"},{"key":"2026042105201717000_16.4.e113901.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-021-00612-6"},{"key":"2026042105201717000_16.4.e113901.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.09.069"},{"key":"2026042105201717000_16.4.e113901.10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.22597","article-title":"Comparison of Midterm Outcomes Associated With Aspirin and Ticagrelor vs Aspirin Monotherapy After Coronary Artery Bypass Grafting for Acute Coronary Syndrome","volume":"4","author":"Bj\u00f6rklund","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026042105201717000_16.4.e113901.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3197"},{"key":"2026042105201717000_16.4.e113901.12","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2508026","article-title":"Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome","volume":"393","author":"Jeppsson","year":"2025","journal-title":"N Engl J Med"},{"key":"2026042105201717000_16.4.e113901.13","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8010104","article-title":"Clopidogrel versus Ticagrelor for Secondary Prevention after Coronary Artery Bypass Grafting","volume":"8","author":"Chang","year":"2019","journal-title":"J Clin Med"},{"key":"2026042105201717000_16.4.e113901.14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjcard.2021.02.026","article-title":"Comparison of Aspirin Monotherapy versus Dual Antiplatelet Therapy Following Coronary Artery Bypass Grafting","volume":"148","author":"Hess","year":"2021","journal-title":"Am J Cardiol"},{"key":"2026042105201717000_16.4.e113901.15","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020413","article-title":"Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery","volume":"10","author":"Qu","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026042105201717000_16.4.e113901.16","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.80.5.1190"},{"key":"2026042105201717000_16.4.e113901.17","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.jtcvs.2015.08.066","article-title":"Dual antiplatelet therapy use by Canadian cardiac surgeons","volume":"150","author":"Yanagawa","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026042105201717000_16.4.e113901.18","first-page":"540","article-title":"Antiplatelet Therapy after Coronary Artery Bypass Graft Surgery \u2013 Unevenness of Daily Clinical Practice","volume":"60","author":"Sopek-Merka\u0161","year":"2022","journal-title":"Acta Clin Croat"},{"key":"2026042105201717000_16.4.e113901.19","first-page":"51","article-title":"Early use of albumin may increase the risk of sepsis-associated acute kidney injury in sepsis patients: a target trial emulation","volume":"12","author":"Li","year":"2025","journal-title":"Mil Med Res"},{"key":"2026042105201717000_16.4.e113901.20","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1007\/s00134-025-07979-x","article-title":"Sodium bicarbonate administration for metabolic acidosis in the intensive care unit: a target trial emulation","volume":"51","author":"Blank","year":"2025","journal-title":"Intensive Care Med"},{"key":"2026042105201717000_16.4.e113901.21","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.202406-1162OC","article-title":"Early versus Delayed Switching from Controlled to Assisted Ventilation: A Target Trial Emulation","volume":"211","author":"Reep","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026042105201717000_16.4.e113901.22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.21383"},{"key":"2026042105201717000_16.4.e113901.23","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-021-06454-7"},{"key":"2026042105201717000_16.4.e113901.24","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamainternmed.2020.2033","article-title":"Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19","volume":"180","author":"Liang","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2026042105201717000_16.4.e113901.25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jcin.2020.12.005","article-title":"Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity: Analysis From ADAPT-DES","volume":"14","author":"Chau","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"2026042105201717000_16.4.e113901.26","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13907","article-title":"Early administration of ketorolac after cardiac surgery and postoperative complications: Analysis of the MIMIC-IV database","volume":"17","author":"Liu","year":"2024","journal-title":"Clin Transl Sci"},{"key":"2026042105201717000_16.4.e113901.27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-075707","article-title":"Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised DACAB trial","volume":"385","author":"Zhu","year":"2024","journal-title":"BMJ"},{"key":"2026042105201717000_16.4.e113901.28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.11966"},{"key":"2026042105201717000_16.4.e113901.29","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2023-323097"},{"key":"2026042105201717000_16.4.e113901.30","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1007\/s00134-025-08135-1","article-title":"Dexmedetomidine for treatment of hyperactive delirium in non-intubated ICU patients: the 4D randomized clinical trial","volume":"51","author":"Godet","year":"2025","journal-title":"Intensive Care Med"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-113901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:20:39Z","timestamp":1776774039000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-113901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,21]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/bmjopen-2025-113901"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-113901","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}